Previous close | 1.190 |
Open | 1.200 |
Bid | 1.180 x 0 |
Ask | 1.200 x 0 |
Day's range | 1.170 - 1.200 |
52-week range | 0.800 - 2.950 |
Volume | |
Avg. volume | 1,859,540 |
Market cap | 1.53B |
Beta (5Y monthly) | 0.18 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.310 |
Earnings date | 13 Aug 2024 - 19 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 5.91 |
CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the European Commission (EC) has approved sugemalimab (Brand name: Cejemly®) in combination with platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small-cell lung cancer (NSCLC) with no sensitizing EGFR mutations, or ALK, ROS1 or RET genomic tumour aberrations. Sugemal
CStone Pharmaceuticals (HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of sugemalimab in combination with chemotherapy as a first-line treatment for metastatic non-small cell lung cancer (NSCLC), which is one of the largest cancer indications and a le
CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the abstract containing the preliminary data from the first-in-human, global, multi-regional, phase 1a/1b study of CS5001 (ROR1 ADC) in patients with advanced solid tumors and lymphomas has been published on the website of the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting. Additional up-to-date clin